<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>20(1)</volume><submitter>Cheli Y</submitter><journal>Molecular cancer</journal><pagination>21</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7839296</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity.</pubmed_title><pmcid>PMC7839296</pmcid><pubmed_authors>Bertolotto C</pubmed_authors><pubmed_authors>Gesson M</pubmed_authors><pubmed_authors>Tulic MK</pubmed_authors><pubmed_authors>Bille K</pubmed_authors><pubmed_authors>Strub T</pubmed_authors><pubmed_authors>Beranger GE</pubmed_authors><pubmed_authors>Montaudie H</pubmed_authors><pubmed_authors>Ballotti R</pubmed_authors><pubmed_authors>Cheli Y</pubmed_authors><pubmed_authors>Nottet N</pubmed_authors><pubmed_authors>Jacquel A</pubmed_authors><pubmed_authors>Picard-Gauci A</pubmed_authors><pubmed_authors>Close P</pubmed_authors><pubmed_authors>Passeron T</pubmed_authors><pubmed_authors>El Hachem N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity.</name><description/><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jan</publication><modification>2025-05-31T22:41:03.643Z</modification><creation>2025-05-31T22:41:03.643Z</creation></dates><accession>S-EPMC7839296</accession><cross_references><pubmed>33504341</pubmed><doi>10.1186/s12943-021-01319-5</doi></cross_references></HashMap>